TP53 can inhibit tumor growth and development by not only downregulating glucose transporters (GLUT1 and GLUT4) but suppressing the activity of glycolytic enzymes, which was verified in the constructed model (Duffy et al., 2020; Huang, 2021; Liu et al., 2021). Here, SLC2A4 is linked to neoplasm.